A dominant-negative form of transcription factor MEF2 inhibits myogenesis - PubMed (original) (raw)
. 1997 Dec 26;272(52):33271-8.
doi: 10.1074/jbc.272.52.33271.
Affiliations
- PMID: 9407117
- DOI: 10.1074/jbc.272.52.33271
Free article
A dominant-negative form of transcription factor MEF2 inhibits myogenesis
O I Ornatsky et al. J Biol Chem. 1997.
Free article
Abstract
A biological role for MEF2 (myocyte enhancer factor 2) activity during mammalian myogenesis has been inferred but not directly proven because of its role in the transcriptional activation of many muscle-specific genes. Therefore, our purpose was to determine whether MEF2 activity is absolutely required for mammalian myogenesis. Using a dominant-negative approach to address this question, we constructed a mutated MEF2A protein comprised of the amino-terminal DNA binding/dimerization domain of MEF2A without its trans-activation domain as a bacterial fusion protein (GST-131) or in a eukaryotic expression vector (pcDNA-131). GST-131 and the protein encoded by pcDNA-131 bind specifically to the MEF2 cis element and abrogate trans-activation of a MEF2-responsive luciferase reporter gene by wild type MEF2A, thus serving a role as trans-dominant inhibitors of MEF2 function. In congruence with their ability to interfere with wild type MEF2 function, microinjection of GST-131 or pcDNA-131 into L6E9 or C2C12 myoblasts inhibited myotube formation. Immunofluorescence analysis showed that the expression of myogenin, myosin heavy chain, and MEF2A were inhibited in the GST-131 or pcDNA-131-injected cells compared with GST or pcDNA-injected controls. We also document that this trans-dominant MEF2 inhibitor impairs the myogenic conversion of C3H10T1/2 fibroblasts by MyoD. Thus, these data provide evidence that the trans-activation function of the MEF2 proteins during mammalian myogenesis is required for muscle-specific gene expression and differentiation.
Similar articles
- MEF2 protein expression, DNA binding specificity and complex composition, and transcriptional activity in muscle and non-muscle cells.
Ornatsky OI, McDermott JC. Ornatsky OI, et al. J Biol Chem. 1996 Oct 4;271(40):24927-33. doi: 10.1074/jbc.271.40.24927. J Biol Chem. 1996. PMID: 8798771 - Myocyte enhancer factor 2C and myogenin up-regulate each other's expression and induce the development of skeletal muscle in P19 cells.
Ridgeway AG, Wilton S, Skerjanc IS. Ridgeway AG, et al. J Biol Chem. 2000 Jan 7;275(1):41-6. doi: 10.1074/jbc.275.1.41. J Biol Chem. 2000. PMID: 10617583 - Transactivation of capn2 by myogenic regulatory factors during myogenesis.
Dedieu S, Mazères G, Dourdin N, Cottin P, Brustis JJ. Dedieu S, et al. J Mol Biol. 2003 Feb 14;326(2):453-65. doi: 10.1016/s0022-2836(02)01310-4. J Mol Biol. 2003. PMID: 12559913 - Skeletal muscle mass is controlled by the MRF4-MEF2 axis.
Schiaffino S, Dyar KA, Calabria E. Schiaffino S, et al. Curr Opin Clin Nutr Metab Care. 2018 May;21(3):164-167. doi: 10.1097/MCO.0000000000000456. Curr Opin Clin Nutr Metab Care. 2018. PMID: 29389722 Review. - Myocyte Enhancer Factor 2A Plays a Central Role in the Regulatory Networks of Cellular Physiopathology.
Liu B, Ou WC, Fang L, Tian CW, Xiong Y. Liu B, et al. Aging Dis. 2023 Apr 1;14(2):331-349. doi: 10.14336/AD.2022.0825. eCollection 2023 Apr 1. Aging Dis. 2023. PMID: 37008050 Free PMC article. Review.
Cited by
- microRNA Temporal-Specific Expression Profiles Reveal longissimus dorsi Muscle Development in Tianzhu White Yak.
Shi B, Zhu C, Wang X, Qi Y, Hu J, Liu X, Wang J, Hao Z, Zhao Z, Zhang X. Shi B, et al. Int J Mol Sci. 2024 Sep 21;25(18):10151. doi: 10.3390/ijms251810151. Int J Mol Sci. 2024. PMID: 39337635 Free PMC article. - Functional analysis of protein interactions using coupled bi-fluorescence complementation/GFP nanobody techniques.
Miyake T, McDermott JC. Miyake T, et al. Nucleic Acids Res. 2024 Aug 12;52(14):e66. doi: 10.1093/nar/gkae548. Nucleic Acids Res. 2024. PMID: 38932691 Free PMC article. - Direct regulation of FNIP1 and FNIP2 by MEF2 sustains MTORC1 activation and tumor progression in pancreatic cancer.
Xia L, Nie T, Lu F, Huang L, Shi X, Ren D, Lu J, Li X, Xu T, Cui B, Wang Q, Gao G, Yang Q. Xia L, et al. Autophagy. 2024 Mar;20(3):505-524. doi: 10.1080/15548627.2023.2259735. Epub 2023 Sep 29. Autophagy. 2024. PMID: 37772772 Free PMC article. - Identification of Robust and Key Differentially Expressed Genes during C2C12 Cell Myogenesis Based on Multiomics Data.
Zhang S, Zhang Y, Chen C, Hu Q, Fu Y, Xu L, Wang C, Liu Y. Zhang S, et al. Int J Mol Sci. 2022 May 26;23(11):6002. doi: 10.3390/ijms23116002. Int J Mol Sci. 2022. PMID: 35682680 Free PMC article. - Targeting MEF2D-fusion Oncogenic Transcriptional Circuitries in B-cell Precursor Acute Lymphoblastic Leukemia.
Tsuzuki S, Yasuda T, Kojima S, Kawazu M, Akahane K, Inukai T, Imaizumi M, Morishita T, Miyamura K, Ueno T, Karnan S, Ota A, Hyodo T, Konishi H, Sanada M, Nagai H, Horibe K, Tomita A, Suzuki K, Muramatsu H, Takahashi Y, Miyazaki Y, Matsumura I, Kiyoi H, Hosokawa Y, Mano H, Hayakawa F. Tsuzuki S, et al. Blood Cancer Discov. 2020 Jun 10;1(1):82-95. doi: 10.1158/2643-3230.BCD-19-0080. eCollection 2020 Jul. Blood Cancer Discov. 2020. PMID: 34661142 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials